Search results for "asm"

showing 10 items of 16598 documents

Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases

2020

Background: Brain metastases (BM) have become a major challenge in patients with metastatic breast cancer. Methods: The aim of this analysis was to characterize patients with asymptomatic BM (n = 580) in the overall cohort of 2589 patients with BM from our Brain Metastases in Breast Cancer Network Germany (BMBC) registry. Results: Compared to symptomatic patients, asymptomatic patients were slightly younger at diagnosis (median age: 55.5 vs. 57.0 years, p = 0.01), had a better performance status at diagnosis (Karnofsky index 80&ndash

0301 basic medicineCancer Researchmedicine.medical_specialtyNeoplasm metastasisMetastasePrognoseContext (language use)lcsh:RC254-282AsymptomaticGastroenterologyArticle03 medical and health sciencesbreast cancer0302 clinical medicineBreast cancerbrain metastasesInternal medicineBrustkrebsasymptomaticMedicineClinical significanceddc:610Treatment outcomeHirnmetastasePerformance statusbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMetastatic breast cancer030104 developmental biologyRisk factorsOncologyLead time bias030220 oncology & carcinogenesisCohortBreast neoplasmsmedicine.symptombusinessDDC 610 / Medicine & healthCancers
researchProduct

Identification of clinical phenotypes and related survival in patients with large hccs

2021

Background. Hepatocellular carcinoma (HCC) factors, especially maximum tumor diameter (MTD), tumor multifocality, portal vein thrombosis (PVT), and serum alpha-fetoprotein (AFP), influence survival. Aim. To examine patterns of tumor factors in large HCC patients. Methods. A database of large HCC patients was examined. Results. A multiple Cox proportional hazard model on death identified low serum albumin levels and the presence of PVT and multifocality, with each having a hazard ratio ≥2.0. All combinations of these three parameters were examined in relation to survival. Using univariate Cox analysis, the combination of albumin &gt

0301 basic medicineCancer Researchmedicine.medical_specialtyPVTSettore MED/12 - GASTROENTEROLOGIASerum albuminlcsh:RC254-282GastroenterologyArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinePlateletHCCneoplasmsSurvival ratePVT.biologybusiness.industryProportional hazards modelAlbuminHazard ratioSettore MED/09 - MEDICINA INTERNAAlbuminMultifocalityHCC; large; phenotypes; PVT; multifocality; albuminlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseasesPortal vein thrombosisAlbumin; HCC; Large; Multifocality; Phenotypes; PVTPhenotypesPhenotype030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomabiology.proteinLargebusiness
researchProduct

Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Tr…

2019

Background: Isometric paravertebral muscle training (IPMT) may improve mobility, pain, and quality of life (QOL) in cancer patients with spinal metastases. However, this regimen remains unproven in patients with unstable spinal metastases (USM), a population at high risk for clinical exacerbation with such interventions. Thus, we conducted this exploratory, non-blinded, randomized controlled trial (NCT02847754) to evaluate the safety/feasibility of IPMT and secondarily assess pain, bone density, pathologic fracture rate, and QOL. Methods: All patients had histologically/radiologically confirmed USM (per Taneichi score) and underwent non-operative management with 5&ndash

0301 basic medicineCancer Researchmedicine.medical_specialtyPathologic fractureVisual analogue scalePopulationunstablelcsh:RC254-282Articlelaw.inventionspine metastases03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawInternal medicineClinical endpointMedicineeducationeducation.field_of_studytrainingbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseRegimen030104 developmental biologyMuscle relaxationOncology030220 oncology & carcinogenesispalliative radiotherapybusinessCancers
researchProduct

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

0301 basic medicineCancer Researchmedicine.medical_specialtyPathologysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHCC; immunotherapy; liver cancer; management; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHepatocellularGeneral MedicineHepatologymedicine.disease030104 developmental biologyOncologyFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisbusinessLiver cancermanagementFuture Oncology
researchProduct

VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherap…

2020

Background: Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even with a multimodality treatment more than half of patients will relapse following surgical resection. Patients who have a poor response to neoadjuvant chemotherapy and have an incomplete (R1) resection or have metastatic lymph nodes in the resection specimen (N+) are especially at risk of recurrence. Current clinical practice is to continue with the same chemotherapy in the adjuvant setting as before surgery. In the phase II randomized EORTC VESTIGE trial (NCT03443856), patients with high risk resected gastric or esophageal adenocarcinoma …

0301 basic medicineCancer Researchmedicine.medical_specialtyPhases of clinical researchIpilimumabchemotherapylcsh:RC254-282gastroesophageal cancer03 medical and health sciences0302 clinical medicineadjuvantClinical endpointMedicineddc:610ipilimumabperioperativenivolumabbusiness.industrygastric cancerStandard treatmentgastric cancer gastroesophageal cancer immunotherapy chemotherapy adjuvant nivolumab ipilimumab perioperativePerioperativeEsophageal cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseClinical TrialSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisimmunotherapyNivolumabbusinessadjuvant; chemotherapy; gastric cancer; gastroesophageal cancer; immunotherapy; ipilimumab; nivolumab; perioperativemedicine.drug
researchProduct

Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer

2019

Patients with non-muscle invasive bladder cancer (NMIBC) undergo lifelong monitoring based on repeated cystoscopy and urinary cytology due to the high recurrence rate of this tumor. Nevertheless, these techniques have some drawbacks, namely, low accuracy in detection of low-grade tumors, omission of pre-neoplastic lesions and carcinomas in situ (CIS), invasiveness, and high costs. This work aims to identify a urinary metabolomic signature of recurrence by proton Nuclear Magnetic Resonance (1H NMR) spectroscopy for the follow-up of NMIBC patients. To do this, changes in the urinary metabolome before and after transurethral resection (TUR) of tumors are analyzed and a Partial Least Square Dis…

0301 basic medicineCancer Researchmedicine.medical_specialtyUrinary systemmetaboliteUrologylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineMetabolomicsCytologyMetabolomeMedicineUrologiametabolic pathwaysCàncerBladder cancermedicine.diagnostic_testbusiness.industryrecurrence predictionCystoscopymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmetabolomicsnuclear magnetic resonance030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)bladder cancerbiomarkerbusinessNon muscle invasivebiomarker bladder cancer metabolic pathways metabolite metabolomics nuclear magnetic resonance recurrence predictionCancers
researchProduct

A 10-year retrospective study of melanoma stage at diagnosis in the academic emergency hospital of Sibiu county

2019

Melanoma is considered to be the most aggressive skin cancer, with an increasing incidence worldwide. An accurate staging of melanoma is crucial in describing the cancer status, estimating prognosis and deciding the optimal treatment solution. In the present study, melanoma staging highlights the importance of early detection, most of the patients having been diagnosed with advanced stages of this skin cancer. A retrospective study was conducted among 117 patients of the Academic Emergency County Hospital of Sibiu, diagnosed with melanoma between 2007 and 2016. The staging of the patients with melanoma was made using the American Joint Committee on Cancer (AJCC) 7th edition, and reconsidere…

0301 basic medicineCancer Researchmedicine.medical_specialtybusiness.industryMelanomaMortality rateGeneral surgeryIncidence (epidemiology)CancerRetrospective cohort studyMelanoma stageArticlesmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesismedicineSkin cancerStage (cooking)businessneoplasms
researchProduct

Adjuvant Radiotherapy After Minimally Invasive Surgery in Patients With Stage IA1-IIA1 Cervical Cancer

2021

To estimate whether adjuvant radiotherapy is necessary for patients with stage IA1-IIA1 cervical cancer after laparoscopic hysterectomy, 221 patients were retrospectively analyzed. Sixty-two of them were treated with laparoscopic hysterectomy and adjuvant radiotherapy (group A), 115 underwent open surgery (group B) and 44 received laparoscopic hysterectomy alone (group C). Results showed that the 3-year local recurrence-free survival (LRFS) rates of group A, B and C were 98.4%, 97.4% and 86.4%, respectively. The LRFS rates of group A and B surpassed C (A vs. B, p=0.634; A vs. C, p=0.011; B vs. C, p=0.006). The inter-group differences of 3-year overall survival (OS) and distant metastasis fr…

0301 basic medicineCancer Researchmedicine.medical_specialtycervical cancerUrologySubgroup analysissurvivalGroup AGroup Bopen surgery03 medical and health sciences0302 clinical medicinemedicineStage (cooking)minimally invasive surgeryRC254-282Original ResearchCervical cancerAdjuvant radiotherapybusiness.industryOpen surgeryLaparoscopic hysterectomyNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesislaparoscopic hysterectomybusinessadjuvant radiotherapyFrontiers in Oncology
researchProduct

A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers

2018

Single nucleotide polymorphisms (SNPs) in DNA glycosylase genes involved in the base excision repair (BER) pathway can modify breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We previously found that SNP rs34259 in the uracil-DNA glycosylase gene (UNG) might decrease ovarian cancer risk in BRCA2 mutation carriers. In the present study, we validated this finding in a larger series of familial breast and ovarian cancer patients to gain insights into how this UNG variant exerts its protective effect. We found that rs34259 is associated with significant UNG downregulation and with lower levels of DNA damage at telomeres. In addition, we found that this SNP is associated with…

0301 basic medicineCancer Researchmedicine.medical_specialtyendocrine system diseasesUracil-DNA glycosylaseEuropean Regional Development Fundlcsh:RC254-282Polymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineBRCA2 MutationRisk FactorsPolitical scienceHealthy volunteersGeneticsmedicineHumansSNPGenetic Predisposition to DiseaseUracil-DNA Glycosidaseskin and connective tissue diseasesResearch ArticlesBRCA2 ProteinOvarian NeoplasmsNetwork onOxidative stress susceptibilityGeneral MedicineMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseBRCA2female genital diseases and pregnancy complicationsuracil‐DNA glycosylase030104 developmental biologyCancer risk modifierOncology030220 oncology & carcinogenesisFamily medicineMutationMolecular MedicineDNA damageFemaleChristian ministryTelomere damageOvarian cancerHuman cancerResearch Article
researchProduct

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

2021

Simple Summary Childhood cancers are mostly of unknown etiology and represent devastating diagnoses. The clinical benefits of steadily increasing tumor control and survival rates are countered by severe and fatal health consequences from genotoxic therapies in long-term survivors of pediatric cancers. Among them, iatrogenic second primary malignancies represent the heaviest burden for the patient. Therefore, particularly in pediatric tumor patients, the reduction of genotoxic treatments and the use of targeted or immune-based oncologic strategies are of high clinical interest. The knowledge of therapy-associated as well as intrinsic risk factors for late sequelae of antineoplastic treatment…

0301 basic medicineCancer Researchmedicine.medical_specialtyetiologymedicine.medical_treatmentPopulationReviewchemotherapyTargeted therapy03 medical and health sciences0302 clinical medicineEpidemiologymedicinechildhood cancerlate-effectseducationIntensive care medicineradiotherapyRC254-282education.field_of_studyChemotherapybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyPediatric cancerRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisEtiologyepidemiologyimmunotherapybusinesssecond primary malignancyCancers
researchProduct